Literature DB >> 12842123

The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade.

Ludovic Leriche1, Jean-Charles Schwartz, Pierre Sokoloff.   

Abstract

N-methyl-D-aspartate (NMDA)/glutamate receptor antagonists, like phencyclidine, generate schizophrenic-like symptoms in humans and behavioural abnormalities in animals, such as hyperactivity. We investigated the role of the dopamine D(3) receptor in locomotor hyperactivity produced in mice by dizocilpine (MK-801), another NMDA receptor antagonist, at a low dose (0.12 mg/kg). BP 897, a highly D(3) receptor-selective partial agonist, or nafadotride, a preferential D(3) receptor antagonist, both at low doses (1 mg/kg and lower), had no effects on spontaneous activity and completely inhibited MK-801-induced hyperactivity. Clozapine, an atypical antipsychotic, produced the same effect as BP 897 and nafadotride. Haloperidol, a typical antipsychotic, reduced both spontaneous activity and MK-801-induced hyperactivity. In D(3) receptor knockout mice, MK-801-induced hyperactivity was weaker than that observed in wild-type mice while BP 897 and nafadotride were inactive. On the contrary, the effects of clozapine and haloperidol, which target multiple receptors in addition to the D(3) receptor, were almost completely preserved in D(3) receptor knockout mice. Our results show that hyperactivity produced by a low dose of MK-801 is dependent upon D(3) receptor stimulation and constitutes the first simple response to assess the in vivo activity of D(3) receptor-selective drugs. In addition, since D(3) receptor antagonists and antipsychotics produced very similar effects, our results add to the growing evidence suggesting that D(3) receptor blockade might produce antipsychotic effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12842123     DOI: 10.1016/s0028-3908(03)00145-x

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  17 in total

Review 1.  The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Authors:  Christian A Heidbreder; Eliot L Gardner; Zheng-Xiong Xi; Panayotis K Thanos; Manolo Mugnaini; Jim J Hagan; Charles R Ashby
Journal:  Brain Res Brain Res Rev       Date:  2005-07

2.  Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics.

Authors:  Andrea M Bradford; Kevin M Savage; Declan N C Jones; Mikhail Kalinichev
Journal:  Psychopharmacology (Berl)       Date:  2010-07-31       Impact factor: 4.530

Review 3.  Neurotoxins and neurotoxicity mechanisms. An overview.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

4.  F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.

Authors:  A Newman-Tancredi; M-B Assié; J-C Martel; C Cosi; L Bruins Slot; C Palmier; I Rauly-Lestienne; F Colpaert; B Vacher; D Cussac
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

5.  Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.

Authors:  Gregory T Collins; Jeffrey M Witkin; Amy H Newman; Kjell A Svensson; Peter Grundt; Jianjing Cao; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2005-04-15       Impact factor: 4.030

Review 6.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

Review 7.  Animal models of serotonergic psychedelics.

Authors:  James B Hanks; Javier González-Maeso
Journal:  ACS Chem Neurosci       Date:  2012-09-24       Impact factor: 4.418

8.  Y-QA31, a novel dopamine D3 receptor antagonist, exhibits antipsychotic-like properties in preclinical animal models of schizophrenia.

Authors:  Xue Sun; Hong-yan Gou; Fei Li; Guan-yi Lu; Rui Song; Ri-fang Yang; Ning Wu; Rui-bin Su; Bin Cong; Jin Li
Journal:  Acta Pharmacol Sin       Date:  2016-01-18       Impact factor: 6.150

9.  Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists.

Authors:  Gregory T Collins; Amy Hauck Newman; Peter Grundt; Kenner C Rice; Stephen M Husbands; Cédric Chauvignac; Jianyong Chen; Shaomeng Wang; James H Woods
Journal:  Psychopharmacology (Berl)       Date:  2007-03-29       Impact factor: 4.530

10.  Dopamine D3 receptor ligands modulate the acquisition of morphine-conditioned place preference.

Authors:  Henriette Francès; Maria Smirnova; Ludovic Leriche; Pierre Sokoloff
Journal:  Psychopharmacology (Berl)       Date:  2004-04-17       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.